Saturday 17 October 2026
Export RDGT’s income statement to Excel — free account
Ridgetech Inc.
RDGT Healthcare Pharmaceutical Retailers
Ridgetech Inc.’s revenue for fiscal 2026 (year ended March 2026) was $132.2 million, up 10.2% from fiscal 2025. Insiders bought in the last twelve months.
0.84
0.01
+1.20%
Follow RDGT
| Older periods | Mar '22 | Sep '22 | Mar '23 | Sep '25 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
3 | 6 | 4 | — |
| (37.28%) | (15.90%) | (114.72%) | 0.00% | ||
| (9.05%) | (3.84%) | (24.67%) | 0.00% | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(44.83%) | (18.62%) | (137.93%) | 0.00% | |
Average Days of Receivables |
34.86 | 32.03 | 19.63 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(5.10) | 8.06 | (8.67) | 10.76 | |
| Other line items | |||||
Cash ROIC |
(8.57%) | 15.26% | (17.48%) | 22.50% | |
Accounts Receivable Turnover |
12.49 | 13.46 | 17.74 | 0.00 | |
Accounts Payable Turnover |
7.08 | 9.01 | 8.52 | 0.00 | |
Inventory Turnover |
12.40 | 13.11 | 14.95 | 0.00 | |
Average Days of Payables |
53.96 | 50.09 | 40.64 | 0.00 | |
Days of Inventory on Hand |
32.76 | 30.10 | 23.27 | 0.00 | |
Tax Rate |
0.13 | 0.63 | 0.07 | — | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | — | |
Selling, General and Administrative Expense of Revenue |
25.46% | 23.35% | 30.10% | — | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | — | |
Interest Coverage |
0.00 | 0.00 | 0.00 | — | |
Operating CF/Net income |
0.53 | (2.05) | 0.36 | 0.00 | |
Depreciation/Fixed assets |
0.09 | 0.10 | 0.10 | 160.79 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | — | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | — |
Columns are period end dates